阿里巴巴(09988.HK就「雙11」商標註冊上訴案被駁回
阿里巴巴(09988.HK)與國家知識產權局就訴爭商標為阿里巴巴於2019年1月申請註冊的「雙11」商標,二審頒布行政判決書。
二審判決書顯示,訴爭商標由文字「雙11」構成,整體易被理解為「十一月十一日」,在實際使用中相關公眾易將其識別為用於表示某一特定日期。訴爭商標指定使用在復審服務上,相關公眾難以將其識別為標示複審服務來源的商標,缺乏顯著性。二審庭審判決駁回上訴。
一審法院認為,阿里巴巴提交的證據尚不足以證明訴爭商標經使用已在復審服務上獲得可供註冊的顯著性,且提出的其他商標獲准註冊的事實與本案情況不同,不能作為訴爭商標應當予以初步審定公告的當然依據。故判決駁回阿里巴巴訴訟請求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.